Scott Ingrid U, Flynn Harry W, Rosenfeld Philip J
Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida 33101, USA.
Am J Ophthalmol. 2003 Oct;136(4):737-9. doi: 10.1016/s0002-9394(03)00266-6.
To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME).
Interventional case series.
Two patients with ICME were treated with intravitreal triamcinolone.
In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 microm before and 197 microm posttreatment in the right eye and 542 microm before and 190 microm posttreatment in the left eye. In another patient, best-corrected acuity was 20/200 before treatment and 20/50 5 months posttreatment; foveal thickness was 580 microm before and 208 microm posttreatment. Recurrence of macular edema responded to repeat intravitreal triamcinolone acetonide in both patients.
Intravitreal triamcinolone may be associated with reduced edema and improved vision in patients with ICME; however, these changes may be transient.
报告玻璃体内注射曲安奈德治疗特发性黄斑囊样水肿（ICME）。
干预性病例系列。
两名ICME患者接受了玻璃体内注射曲安奈德治疗。
一名患者，治疗前双眼最佳矫正视力为20/70，治疗后6个月为20/30。右眼治疗前黄斑中心凹厚度为606微米，治疗后为197微米；左眼治疗前为542微米，治疗后为190微米。另一名患者，治疗前最佳矫正视力为20/200，治疗后5个月为20/50；黄斑中心凹厚度治疗前为580微米，治疗后为208微米。两名患者黄斑水肿复发时再次玻璃体内注射曲安奈德均有效。
玻璃体内注射曲安奈德可能使ICME患者水肿减轻、视力提高；然而，这些变化可能是短暂的。
